md-medicaldata

Authors

 

Dajana Dedić Novaković^1,2, Svetlana Popović-Petrović^1,2, Rastislava Krasnik^1,3, Nemanja Novaković², Aleksandra Kovač ^1,2, Jelena Zvekić-Svorcan<sup>1,4

1</sup>Medicinski fakultet Novi Sad, Univerzitet u Novom Sadu, Srbija
²Institut za onkologiju Vojvodine, Sremska Kamenica, Srbija
³Institut za zdravstvenu zaštitu dece i omladine Vojvodine, Novi Sad,
⁴Specijalna bolnica za reumatske bolesti, Novi Sad, Srbija

 

UDK: 618.11-006.6-085.06

The paper was received / Rad primljen: 26.10.2023.

Accepted / Rad prihvaćen: 04.12.2023.

 

Correspondence to:

dr Dajana Dedić Novaković
Institut za onkologiju Vojvodine, Sremska Kamenica
Medicinski fakultet Novi Sad, Univerzitet u Novom Sadu
Tel: +381 69 4973833
e-mail: dedic.dajana@onk.ns.ac.rs
e-mail: 1414d20@mf.uns.ac.rs

 

 

Sažetak

 

 

Jedna od najučestalijih funkcionalnih komplikacija koja nastaje kao posledica lečenja karcinoma jajnika je polineuropatija izazvana hemioterapeuticima (eng. CIPN, Chemotherapy-induced peripheral neuropathy). Polineuropatija izazvana hemioterapeuticima predstavlja oštećenje senzornih, motornih i autonomnih nervnih vlakana koje za posledicu dovodi do promena u senzibilitetu, motornih ispada i poremećaja vegetativnog nervnog sistema. Ova vrsta polineuropatije se može razviti kao posledica terapije jednim ili kombinacije više hemioterapeutika, uključujući preparate na bazi platine, taksane, vinka alkaloide, talidomid i bortezomib. Stepen polineuropatije zavisi od primljene doze hemioterapeutika, od vrste i kombinacije lekova, kao i od ukupne, kumulativne doze.  Postavljanje dijagnoze polineuropatije uzrokovane hemioterapeuticima se bazira na kliničkoj slici i prezentovanju i kvantifikaciji simptoma od strane pacijenata putem različitih upitnika.  Postoje mnogobrojni  faramakološki i nefarmakološki aspekti u lečenju CIPN. U kliničkoj praksi od nefarmakoloških metoda lečenja najviše se primenjuje kineziterapija, krioterapija, transkutana električna nervna stimulacija i akupunktura.

 

Ključne reči:

karcinom jajnika, polineuropatija izazvana hemioterapeuticima, nefarmakološki metod

 

 

 

Abstract

 

One of the most common functional complications that occurs as a consequence of chemotherapy in ovarian cancer patients is chemotherapy-induced peripheral neuropathy (CIPN). Aforementioned condition represents impairment of motor, sensory or autonomic nerve function that can lead to sensory alteration, motor nerve damage and autonomic nervous system disfunction. This type of neuropathy can be the result of chemotherapy with single or combination of multiple chemotherapy agents, including platinum based agents, taxoids, vinca alkaloid, thalidomide and bortezomib. Stage of polyneuropathy depends on dose of chemotherapy agent, type and combination of agents, as well as of total cumulative dose of the agents. Arriving at the correct diagnosis of chemotherapy-induced peripheral neuropathy is based not only on good clinical practice but also on presenting and quantifying of symptoms by patients themselves through various questionnaires. There are numerous pharamacological and non-pharamacological aspects in treatment of chemotherapy-induced peripheral neuropathy. The most used non-pharmacological methods in clinical practice are kinesiotherapy, cryotherapy, transcutaneous electrical nerve stimulation and acupuncture.

 

Key words:

ovarian cancer, chemotherapy-induced peripheral neuropathy, non-pharmacological method

 

 

 

 

References:

1. Gaona-Luviano P, Medina-Gaona LA, Magaña-Pérez K. Epidemiology of ovarian cancer. Chin Clin Oncol 2020;9(4):47.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clin. 2021;71:209–49.
3. Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, et al. Ten-year relative survival for epithelial ovarian cancer. Obs Gynecol. 2012;120: 612–8.
4. Chang WI, Kang HC, Wu HG, Kim HJ, Jeon SH, Lee M, et al. Lower Extremity Lymphedema in Gynecologic Cancer Patients: Propensity Score Matching Analysis of External Beam Radiation versus Brachytherapy. Cancers. 2019; 11(10):1471.
5. Graf N, Rufibach K, Schmidt AM, Fehr M, Fink D, Baege AC. Frequency and risk factors of lower limb lymphedema following lymphadenectomy in patients with gynecological malignancies. Eur J Gynaecol Oncol. 2013;34(1):23-7. 
6. Glare PA, Davies PS, Finlay E, Gulati A, Lemanne D, Moryl N, et al. Pain in cancer survivors. J Clin Oncol. 2014;32:1739–47.
7. Brown TJ, Sedhom  R, Gupta A. Chemotherapy-induced peripheral neuropathy. JAMA Oncol. 2019;5(5):750.
8. Stubblefield MD, Burstein HJ, Burton AW, Custodio CM, Deng GE, Ho M, et al. NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw. 2009;7(Suppl 5):S-1.
9. Kolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S, et al. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol. 2016;73:860–6.
10. Mols F, Van de Poll-Franse LV, Vreugdenhil G, Beijers AJ, Kieffer JM, Aaronson NK, et al. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population. Eur J Cancer. 2016;69:28–38.
11. Brown TJ, Sedhom R, Gupta A. Chemotherapy-Induced Peripheral Neuropathy. JAMA Oncol. 2019;5(5):750.
12. Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63(6):419-37.
13. Oneda E, Abeni C, Zanotti L, Zaina E, Bighè S, Zaniboni A. Chemotherapy-induced neurotoxicity in the treatment of gynecological cancers: State of art and an innovative approach for prevention. World J Clin Oncol. 2021;12(6):458-67.
14. Park SJ, Yim GW, Paik H, Lee N, Lee S, Lee M, et al. Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind, randomized study. J Gynecol Oncol. 2021;32(5):e73.
15. Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P, et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol. 2020;31(10):1306-19.  
16. Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006;7:903-9. 
17. Desforges AD, Hebert CM, Spence AL, Reid B, Dhaibar HA, Cruz-Topete D, et al. Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: An update. Biomed pharmacother. 2022;147:112671.
18. Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P, et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol. 2020;31(10):1306-19.
19. Oh PJ, Kim YL. Effectiveness of Non-Pharmacologic Interventions in Chemotherapy Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis. J Korean Acad Nurs. 2018;48(2):123-42.
20. Wilcoxon A, Kober KM, Viele C, Topp K, Smoot B, Abrams G, et al. Association Between Physical Activity Levels and Chemotherapy-Induced Peripheral Neuropathy Severity in Cancer Survivors. Oncol Nurs Forum. 2020;47(6):703-19.
21. Dybeck MM, Adamsen L, Sørensen V, Lillelund C, Møller T, Andersen C. Can supervised group-based multimodal exercise improve health-related quality of life in women with ovarian cancer undergoing chemotherapy? Eur J Cancer Care. 2022;31(4):e13607.
22. Adamsen L, Quist M, Andersen C, Møller T, Herrstedt J, Kronborg D, et al. Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial. BMJ. 2009;339:b3410.
23. Chitkumarn P, Rahong T, Achariyapota V. Efficacy of Siriraj, in-house-developed, frozen gloves for cold therapy reduction of chemotherapy-induced peripheral neuropathy in gynecological cancer patients: randomized controlled trial. Support Care Cancer. 2022;30(6):4835-43.
24. Jia J, Guo Y, Sundar R, Bandla A, Hao Z. Cryotherapy for Prevention of Taxane-Induced Peripheral Neuropathy: A Meta-Analysis. Front Oncol. 2021;11:781812.
25. Sato J, Mori M, Nihei S, Kumagai M, Takeuchi S, Kashiwaba M,  et al. The effectiveness of regional cooling for paclitaxel-induced peripheral neuropathy. J Pharm Health Care Sci. 2016;2:33.
26. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guidelines. J Clin Oncol. 2014;32(18):1941-67.
27. Püsküllüoğlu M, Tomaszewski KA, Grela-Wojewoda A, Pacholczak-Madej R, Ebner F. Effects of Transcutaneous Electrical Nerve Stimulation on Pain and Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Systematic Review. Medicina (Kaunas). 2022;58(2):284. 
28. Gewandter JS, Chaudari J, Ibegbu C, Kitt R, Serventi J, Burke J et al. Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: An open-label feasibility study. Support. Care Cancer. 2019;27:1765–74.
29. Oneda E, Abeni C, Zanotti L, Zaina E, Bighè S, Zaniboni A. Chemotherapy-induced neurotoxicity in the treatment of gynecological cancers: State of art and an innovative approach for prevention. World J Clin Oncol. 2021;12(6):458-67.
30. Tsai CH, Lin YH, Li YS, Ho TL, Hoai Thuong LH, Liu YH. Integrated Medicine for Chemotherapy-Induced Peripheral Neuropathy. Int J Mol Sci. 2021;22(17):9257.
31. Schroeder S, Meyer-Hamme G, Epplée S. Acupuncture for chemotherapy-induced peripheral neuropathy (CIPN): a pilot study using neurography. Acupunct Med. 2012;30(1):4-7.
32. Lu W, Matulonis UA, Dunn JE, Lee H, Doherty-Gilman A, Dean-Clower E, et al. The Feasibility and Effects of Acupuncture on Quality of Life Scores During Chemotherapy in Ovarian Cancer: Results from a Pilot, Randomized Sham-Controlled Trial. Med Acupunct. 2012;24(4):233-40.
33. Cao A, Cartmel B, Li FY, Gottlieb LT, Harrigan M, Ligibel JA, et al. Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy Among Patients Treated for Ovarian Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2023;6(8):e2326463.  
34. Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020;38(28):3325-48.
    

PDF: 12-Dedić Novaković D. et al . MD-Medical Data 2023;15(3) 123-126.pdf